Abstract B018: A high-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced prostate cancer
Keith H. Jansson(National Cancer Institute), Kathleen Kelly(National Cancer Institute), Craig J. Thomas(National Institutes of Health), Alilin Aian Neil(National Cancer Institute), Crystal Tran(National Cancer Institute), Michael L. Beshiri(National Cancer Institute), Eva Corey(University of Washington), John B. Tucker(University of Wisconsin–Madison), Caitlin M. Tice(National Cancer Institute), Ross Lake(National Cancer Institute), Lauren E. Stahl(National Cancer Institute), Paul G. Hynes(National Cancer Institute), David A. Proia(C4 Therapeutics (United States)), Jacob Cawley(National Cancer Institute), Rajarshi Guha(Vertex Pharmaceuticals (United States)), Yasmine C. Abbey(National Cancer Institute), Caitlyn Fuller(National Cancer Institute), Lei Fang(Jiujiang University), Supreet Agarwal(University of Iowa), Xiahu Zhang, John K. Simmons(University of Pittsburgh), Shelley Hoover, Holly M. Nguyen(University of Washington), JuanJuan Yin(National Cancer Institute), Richard J. Simpson(University of Arizona)
Cited by 0
Related Papers
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
|Proceedings of the National Academy of Sciences|1999|632
Proteomics Analysis of A33 Immunoaffinity-purified Exosomes Released from the Human Colon Tumor Cell Line LIM1215 Reveals a Tissue-specific Protein Signature
|Molecular & Cellular Proteomics|2009|583
Increased demand for NAD+ relative to ATP drives aerobic glycolysis
|Molecular Cell|2020|561